A J Scheen

482 total citations
23 papers, 368 citations indexed

About

A J Scheen is a scholar working on Surgery, Endocrinology, Diabetes and Metabolism and Pharmacology. According to data from OpenAlex, A J Scheen has authored 23 papers receiving a total of 368 indexed citations (citations by other indexed papers that have themselves been cited), including 9 papers in Surgery, 7 papers in Endocrinology, Diabetes and Metabolism and 6 papers in Pharmacology. Recurrent topics in A J Scheen's work include Diet and metabolism studies (6 papers), Pharmacology and Obesity Treatment (4 papers) and Lipoproteins and Cardiovascular Health (4 papers). A J Scheen is often cited by papers focused on Diet and metabolism studies (6 papers), Pharmacology and Obesity Treatment (4 papers) and Lipoproteins and Cardiovascular Health (4 papers). A J Scheen collaborates with scholars based in Belgium, France and Australia. A J Scheen's co-authors include Pierre J. Lefèbvre, Nicolas Paquot, Philippe Lefèbvre, J. Delarge, A Luyckx, Luc F. Van Gaal, U Gaspard, Pascal Lefèbvre, Françoise Luyckx and Michel Letiexhe and has published in prestigious journals such as Diabetic Medicine, Diabetes Obesity and Metabolism and Drug Safety.

In The Last Decade

A J Scheen

20 papers receiving 344 citations

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name	h						Papers	Cites
A J Scheen Belgium	9	166	107	79	79	62	23	368
A J Scheen Belgium	7	179 1.1×	150 1.4×	86 1.1×	38 0.5×	55 0.9×	22	351
Wolin Hou China	9	91 0.5×	200 1.9×	106 1.3×	71 0.9×	38 0.6×	11	446
B.A. Nassar United Kingdom	12	103 0.6×	133 1.2×	91 1.2×	67 0.8×	103 1.7×	28	524
Emily J. Johnson United States	8	179 1.1×	134 1.3×	93 1.2×	41 0.5×	26 0.4×	10	398
Kotoko Kosuge Japan	13	120 0.7×	97 0.9×	39 0.5×	54 0.7×	52 0.8×	20	365
J. Schloos Germany	12	161 1.0×	196 1.8×	149 1.9×	53 0.7×	49 0.8×	19	511
Yoshitada Yajima Japan	12	239 1.4×	97 0.9×	54 0.7×	20 0.3×	74 1.2×	28	504
Loren D. Grossman Canada	10	260 1.6×	169 1.6×	71 0.9×	38 0.5×	36 0.6×	15	414
Belma Korkmaz Türkiye	14	94 0.6×	125 1.2×	34 0.4×	58 0.7×	153 2.5×	27	437
Eon Ju Jeon South Korea	11	117 0.7×	60 0.6×	64 0.8×	49 0.6×	61 1.0×	35	357

Countries citing papers authored by A J Scheen

Since Specialization

Citations

This map shows the geographic impact of A J Scheen's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by A J Scheen with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites A J Scheen more than expected).

Fields of papers citing papers by A J Scheen

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by A J Scheen. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by A J Scheen. The network helps show where A J Scheen may publish in the future.

Co-authorship network of co-authors of A J Scheen

This figure shows the co-authorship network connecting the top 25 collaborators of A J Scheen. A scholar is included among the top collaborators of A J Scheen based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with A J Scheen. A J Scheen is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

Lefèbvre, Pierre J., Nicolas Paquot, & A J Scheen. (2015). Inhibiting or antagonizing glucagon: making progress in diabetes care. Diabetes Obesity and Metabolism. 17(8). 720–725. 40 indexed citations

Scheen, A J, et al.. (2013). [Orthostatic hypotension: 2nd part. Epidemiology, complications and treatments].. PubMed. 68(4). 163–70.

Scheen, A J, et al.. (2013). [European guidelines for the management of diabetes, prediabeties and cardiovascular disease. First part. Management of diabetes and cardiovascular risk factors].. PubMed. 68(11). 585–92.

Scheen, A J. (2010). [NAVIGATOR: A trial of prevention of cardiovascular complications and type 2 diabetes with valsartan and/or nateglinide].. PubMed. 65(4). 217–23. 7 indexed citations

Scheen, A J, et al.. (2010). Changes in pulse pressure, heart rate and the pulse pressure × heart rate product during squatting in Type 1 diabetes according to age. Diabetic Medicine. 27(7). 753–761. 4 indexed citations

Scheen, A J. (2008). CB1 Receptor Blockade and its Impact on Cardiometabolic Risk Factors: Overview of the RIO Programme with Rimonabant. Journal of Neuroendocrinology. 20(s1). 139–146. 51 indexed citations

Scheen, A J & Luc F. Van Gaal. (2008). [Sitagliptine (Januvia): incretin enhancer potentiating insulin secretion for the treatment of type 2 diabetes].. PubMed. 63(2). 105–9. 8 indexed citations

Scheen, A J. (2006). [The CHARISMA study: in search of the best antiplatelet strategy for cardiovascular prevention].. PubMed. 61(9). 656–61. 3 indexed citations

Scheen, A J, Françoise Luyckx, & Pascal Lefèbvre. (2006). [How to explore...the metabolic syndrome by its new IDF definition].. PubMed. 61(1). 48–52. 5 indexed citations

10.

Scheen, A J, et al.. (2005). [Insulin detemir (Levemir)].. PubMed. 60(10). 814–9. 4 indexed citations

11.

Scheen, A J, et al.. (2003). [Statins for cardiovascular prevention: is there still a place for cholesterol measurement?].. PubMed. 58(4). 191–7. 1 indexed citations

12.

Scheen, A J, et al.. (2003). [Prevention of type 2 diabetes: lifestyle changes or pharmacological interventions?].. PubMed. 58(4). 206–10. 6 indexed citations

13.

Scheen, A J. (2002). [Clinical study of the month. The LIPS study: fluvastatin for prevention of cardiac events following percutaneous coronary angioplasty].. PubMed. 57(7). 479–82. 2 indexed citations

14.

Scheen, A J. (2001). Hepatotoxicity with Thiazolidinediones. Drug Safety. 24(12). 873–888. 105 indexed citations

15.

Ducobu, Jean & A J Scheen. (2000). [Recommendations of the Belgian Lipid Club for the diagnosis and treatment of hyperlipidemias: summary for the practitioner].. PubMed. 55(5). 360–6.

16.

Gaspard, U, et al.. (1999). Long-term effects of oral estradiol and dydrogesterone on carbohydrate metabolism in postmenopausal women. Climacteric. 2(2). 93–100. 20 indexed citations

17.

Scheen, A J, et al.. (1999). Medical Aspects of Obesity. Acta chirurgica Belgica. 99(3). 135–139. 8 indexed citations

18.

Scheen, A J. (1998). Aggressive weight reduction treatment in the management of type 2 diabetes.. PubMed. 24(2). 116–23. 30 indexed citations

19.

Scheen, A J & Philippe Lefèbvre. (1996). Insulin action in man.. PubMed. 22(2). 105–10. 23 indexed citations

20.

Scheen, A J, et al.. (1986). Diuretic activity of torasemide and furosemide in chronic heart failure: A comparative double blind cross-over study. European Journal of Clinical Pharmacology. 31(S1). 35–42. 38 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact